- Published: 11 December 2015
- Written by Editor
Study Shows Safety of BioPharmX Topical Formulation
Research suggests BPX-01 topical minocycline could be more effective in treatment of acne than other topical treatments
MENLO PARK, Calif., Dec. 11, 2015 -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at ASCB 2015 in San Diego shows its unique formulation of minocycline known as BPX-01 may offer a breakthrough in acne treatment because it can safely deliver the antibiotic to the layer of skin where the condition develops.
Study findings will be presented Monday afternoon at the annual gathering of the American Society of Cell Biology.
Session: Defining Therapeutic Targets and New Therapeutics 2
Time: 1:30pm to 3:00pm
Location: ASCB Learning Center, Exhibit Halls D-H
BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline, the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne because it has a lower resistance rate than other antibiotics.
Topical acne medications available today penetrate the top layer of skin with less effective antibiotics. However, minocycline is generally prescribed as an oral medication due to the lack of availability of effective topical medications. High doses of oral minocycline are associated with various side effects that can discourage compliance.
"Our preliminary findings in animals and in vitro human skin indicate that minocycline delivered by BPX-01 is safely absorbed into the skin, reaching the epidermis and the pilosebaceous unit where acne develops," said Kin F. Chan, Ph.D., executive vice president of research and development at BioPharmX Corporation. "The studies clearly indicate that all doses of BPX-01 were found to be safe and nontoxic for topical use, virtually eliminating risk of undesirable side effects."
The BioPharmX research also found that the hydrophilic BPX-01 formulation distributes evenly, is not sticky and does not occlude or irritate the skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans at any given moment. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
About BioPharmX™ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those section. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding, including with respect to: the success of the commercialization of VI2OLET iodine, the effectiveness of BPX01, the timing with respect to filing an IND and clinical trials for BPX-01, the release of key data for BPX01, the release of key data and the successful completion of multi-site IRB studies for BPX03 and the successful completion of the private placement with Korea Investment Partners Overseas Expansion Platform Fund. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc.